DOI: 10.1001/jamaophthalmol.2024.0101 ISSN: 2168-6165

Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease

Rongmei Peng, Ying Jie, Qin Long, Lan Gong, Lei Zhu, Xingwu Zhong, Shaozhen Zhao, Xiaoming Yan, Hao Gu, Huping Wu, Gang Li, Kaiyun Zhang, Sonja Krösser, Ruxia Xu, Jing Hong
  • Ophthalmology


Dry eye disease (DED) is a prevalent eye disorder. Cyclosporine is an effective immunomodulator that is widely used in DED; however, due to its highly hydrophobic nature, delivery of cyclosporine to the ocular surface is challenging.


To evaluate the efficacy and safety of SHR8028, a water-free cyclosporine ophthalmic solution, 0.1%, compared with vehicle in Chinese participants with DED.

Design, Setting, and Participants

This was a multicenter, double-blind, vehicle-controlled, phase 3 randomized clinical trial conducted from March 4, 2021, to July 22, 2022. Adult participants with moderate to severe DED were recruited from 12 hospitals in China. Study data were analyzed April 2, 2022, for the primary analysis.


Following a 14-day run-in period with an artificial tear, participants were randomly assigned (1:1) to receive water-free cyclosporine or vehicle (1 eye drop in each eye twice daily). After a 29-day treatment, participants of both groups were given the option to receive water-free cyclosporine for an additional 12 weeks for longer-term safety assessment.

Main Outcomes and Measures

The primary end points were changes from baseline in total corneal fluorescein staining (tCFS) using the National Eye Institute scale and in dryness score on a visual analog scale at day 29.


A total of 206 participants (mean [SD] age, 47.8 [14.2] years; 185 female [90%]) were enrolled, with 103 each in the cyclosporine group and the vehicle group. At day 29, the cyclosporine group experienced improved tCFS compared with vehicle (change [Δ] = −1.8; 95% CI, −2.7 to −1.0; P < .001), with a tCFS score decrease from baseline of −4.8 in the cyclosporine group and −3.0 in the vehicle group. Dryness score decreased from baseline in both groups (−19.2 vs −15.4; Δ = −3.8; 95% CI, −9.2 to 1.6; P = .17). During the 29-day treatment, treatment-related adverse events were reported in 15 participants (14.6%) in the cyclosporine group and 11 participants (10.7%) in the vehicle group.

Conclusions And Relevance

Results demonstrated superiority of a water-free cyclosporine, 0.1%, eye solution over vehicle in improving tCFS score at day 29 in Chinese participants with DED. However, dryness score (VAS) was not improved at day 29.

Trial Registration Identifier: NCT05841043

More from our Archive